deltatrials
Completed PHASE3 NCT00134030

Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma

A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-operative Chemotherapy

Sponsor: Children's Oncology Group

Conditions Localized Osteosarcoma Metastatic Osteosarcoma
Interventions Cisplatin Doxorubicin Hydrochloride Etoposide Ifosfamide Methotrexate Peginterferon Alfa-2b Quality-of-Life Assessment Questionnaire Administration Therapeutic Conventional Surgery
Updated 11 times since 2017 Last updated: May 10, 2023 Started: Nov 14, 2005 Primary completion: Jan 31, 2015 Completion: Sep 30, 2022

Listed as NCT00134030, this PHASE3 trial focuses on Localized Osteosarcoma and Metastatic Osteosarcoma and remains completed. Sponsored by Children's Oncology Group, it has been updated 11 times since 2005, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

11 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jul 2023 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Unknown Status → Completed

  5. Jan 2021 — Jul 2023 [monthly]

    Unknown Status PHASE3

▶ Show 6 earlier versions

  1. Jul 2020 — Jan 2021 [monthly]

    Unknown Status PHASE3

    Status: Active Not Recruiting → Unknown Status

  2. Jul 2018 — Jul 2020 [monthly]

    Active Not Recruiting PHASE3

  3. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE3

  4. Jun 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  5. Feb 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE3

  6. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Nov 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Children's Oncology Group
  • Medical Research Council
  • National Cancer Institute (NCI)
  • University College, London
Data source: Children's Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States, Albany, United States, Albuquerque, United States, Amarillo, United States, Ann Arbor, United States, Asheville, United States, Atlanta, United States, Augusta, United States, Aurora, United States, Baltimore, United States and 149 more location s